The dilemma is heart-rending. With COVID-19 infections and hospitalizations rising, the FDA approved two drugs—Paxlovid from Pfizer, and molnupiravir from Merck and Ridgeback—to treat the illness that is killing so many and rendering others permanently disabled. Yet in the United States, many patients can’t get the drug, or even figure out which pharmacy near them […]
Subscribe to:
Post Comments (Atom)
-
Welcome to the weekly edition of Healthcare IT Today Bonus Features . This article will be a weekly roundup of interesting stories, product ...
-
Training artificial intelligence models on more diverse image and data sets can augment decision making, overcome knowledge gaps, and promot...
-
The following is a guest article by Ladd Wiley, Senior Vice President for Global Corporate Affairs, Public Policy, and Advocacy at Epic , ...
No comments:
Post a Comment